JWH-371

JWH-371

0JWH-371 is a synthetic cannabinoid from the JWH series. It was developed by the team of John W. Huffman at Clemson University. It is a potent and selective agonist for the cannabinoid receptor CB2, with a binding affinity of 0.6nM at CB2 vs 23.0nM at CB1.

Chemistry

JWH-371 is part of the JWH series of synthetic cannabinoids, which were developed by John W. Huffman and his team at Clemson University. The JWH series is named after Huffman himself. JWH-371 is a derivative of naphthalen-1-yl-(1-pentylindol-3-yl)methanone, with a tetramethylcyclopropyl group substituted on the indole ring.

Pharmacology

JWH-371 is a potent and selective agonist for the cannabinoid receptor CB2. It has a binding affinity of 0.6nM at CB2, compared to 23.0nM at CB1. This makes it over 38 times more selective for CB2 than CB1. The CB2 receptor is primarily found in the immune system, and is less prevalent in the brain than the CB1 receptor. Activation of the CB2 receptor is associated with anti-inflammatory and analgesic effects.

Legal Status

The legal status of JWH-371 varies by country. In many jurisdictions, it is classified as a controlled substance due to its structural similarity to other synthetic cannabinoids. However, as of 2021, it is not specifically listed in the United Nations' drug control conventions.

See Also

• JWH-018
• JWH-073
• JWH-200
• Synthetic cannabinoids
• Cannabinoid receptor